• SMAIO posted Q1 2026 revenue of EUR 2.8 million, up 11% from EUR 2.6 million year earlier.
• Implant sales rose 12% to EUR 2.8 million from EUR 2.5 million, driven by North America.
• North America revenue climbed 21% to EUR 2.3 million from EUR 1.9 million, despite an adverse EUR/USD impact of about EUR 0.25 million; US represented nearly 80% of activity.
• Revenue outside France fell 23% to EUR 0.3 million from EUR 0.4 million, while France was flat at EUR 0.3 million.
• Excluding currency effects, North America sales increased 35% to USD 2.6 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SMAIO SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260512998596) on May 12, 2026, and is solely responsible for the information contained therein.